Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA

Naomi V Dahl¹

Robert F Kaper²

William E Strauss¹

Frank A Corvino³

Marko Zivkovic³

¹Medical Affairs, ²Medical & Scientific Affairs, AMAG Pharmaceuticals, Inc., Waltham, MA, ³Genesis Research, Hoboken, NJ, USA

Objective: Ferumoxytol has demonstrated superior efficacy compared with oral iron in treating iron deficiency anemia in chronic kidney disease (CKD) patients. However, an economic evaluation of ferumoxytol has not been conducted. The aim of this study was to analyze the cost-effectiveness of treating iron deficiency anemia in adult non-dialysis-dependent CKD patients with ferumoxytol as compared with oral iron, alone or in combination with erythropoietin-stimulating agents (ESAs).

Methods: A decision analytic model compared health outcomes and costs associated with 5-week outpatient treatment of adult non-dialysis-dependent CKD patients with ferumoxytol or oral iron, each as monotherapy or in combination with ESAs in the USA. Direct costs include the following: drug acquisition and administration, adverse events, and medical management. Efficacy was determined as mean increase in hemoglobin (g/dL) from baseline over the 5-week period. Clinical inputs were derived from patient-level data from two Phase III randomized controlled trials of ferumoxytol vs. oral iron in non-dialysis-dependent CKD patients, and cost inputs from RED BOOKTM and Centers for Medicare and Medicaid Services data. Sensitivity analyses were performed to identify cost drivers and assess the stability of results.

Results: The 5-week treatment cost was \$2,489, \$5,216, \$1,298, and \$4,263 per patient for ferumoxytol, ferumoxytol with ESAs, oral iron, and oral iron with ESAs, respectively. The corresponding incremental costs per g/dL increase in hemoglobin, relative to ferumoxytol alone, were \$398, \$3,558, and \$4,768 per patient. Efficacy was the main driver of cost-effectiveness for all treatments. Adverse event and medical management costs were the principal drivers of oral iron monotherapy costs, while drug acquisition substantially contributed to the overall cost for the remaining treatments.

Conclusion: These results suggest that ferumoxytol is a cost-effective treatment for iron deficiency anemia in non-dialysis-dependent CKD patients over a 5-week period compared with oral iron with or without ESAs. Ferumoxytol is more cost-effective as monotherapy.

Keywords: incremental cost-effectiveness ratio, ICER, health care costs, intravenous iron, iron therapy, erythropoietin

Introduction

Chronic kidney disease (CKD) affects more than 10% of adults and is the ninth leading cause of death in the USA.^{1,2} CKD can impair the production of erythropoietin (EPO), a hormone that regulates red blood cell (RBC) production, resulting in anemia.^{3,4} Iron deficiency anemia (IDA) represents the most severe stage of iron deficiency and is clinically diagnosed when hemoglobin (Hb) levels are more than 2 SDs below the mean

Correspondence: Naomi V Dahl
Medical Affairs AMAG Pharmaceuticals,
Inc., 1100 Winter Street, Waltham, MA
02451, USA
Tel +1 617 498 7650
Fax +1 617 902 2420
Email ndahl@amagpharma.com

for a normal individual of the same age and gender living at the same altitude.^{4–6} Among CKD patients, particularly those with severe kidney damage, IDA is associated with a range of symptoms characteristic of all anemias, and also serious complications such as compromised immune system, left ventricular hypertrophy, coronary heart disease, and even stroke.^{4,5,7,8} From 2007 to 2010, anemia prevalence was two times higher among adult CKD patients (15.4%) than in the general population (7.6%) and increased with severity (8.4% at stage 1 and 53.4% at stage 5).⁹

Standard initial IDA therapy in adults in the USA is orally administered iron (e.g., in the form of ferrous salts).¹⁰ Although oral iron is convenient and low in cost, benefits are often impaired by gastrointestinal (GI) side effects, poor treatment adherence (20% of patients develop GI distress and up to 30% discontinue oral treatment), and limited absorption.^{3,6,8,11} For patients who fail to respond to oral iron treatment due to noncompliance, chronic uncorrectable bleeding, oral iron intolerance, or intestinal malabsorption, intravenous (IV) administration is an alternative administration method.^{3,6,8} A recent systematic review and meta-analysis of 24 randomized controlled trials (RCTs), 13 of which included 2,369 patients with CKD stages 3–5, resulted in support for increased use of IV iron for patients with CKD stages 3–5 (not receiving dialysis).¹² In addition, patients diagnosed with IDA due to CKD are often treated with EPO-stimulating agents (ESA) which further increases the demand for iron supplementation in these patients.^{3,4,8,11,13–15}

Ferumoxytol (FER) is a superparamagnetic iron oxide nanoparticle IV formulation approved by the US Food and Drug Administration (FDA) for the treatment of IDA in adult CKD patients.^{3,16,17} Clinical trials have demonstrated that FER significantly increases Hb levels in non-dialysis-dependent CKD (ND-CKD) patients compared with oral iron.^{3,16} FER in combination with ESA provides an incremental increase in Hb levels.³ Patients with lower baseline Hb levels respond better to FER treatment.³ Clinical trial results indicate that irrespective of concurrent ESA utilization, FER yields improved treatment outcomes as compared with oral iron in adult ND-CKD patients.^{3,16}

A health economic analysis of FER compared with oral iron in treating IDA in the adult ND-CKD population is not available in the published literature. Such an evaluation would provide key insights into the cost-effectiveness of FER treatment and an assessment of health economic outcomes for adult ND-CKD patients diagnosed with IDA. Using results of two Phase III randomized controlled clinical trials (NCT00255424, NCT00255437), a health economic model

to evaluate the cost-effectiveness of FER and oral iron, as monotherapy or in conjunction with ESA, for the treatment of IDA in adult ND-CKD patients was developed.

Materials and methods

Model design

A multivariate cost-effectiveness model was developed in Microsoft Excel® to evaluate the direct costs and health outcomes associated with IDA treatment over a 5-week evaluation period in adult ND-CKD patients from the US payers' perspective. Four treatments were compared: FER monotherapy, oral iron monotherapy, FER in combination with ESA, and oral iron in combination with ESA. Direct costs associated with each IDA treatment considered in the model include therapy costs (drug acquisition and administration), adverse event (AE) costs, and medical management costs. The model is based on patient-level clinical data (patient characteristics, treatment efficacy, and safety) from two Phase III RCTs of FER compared with oral iron in ND-CKD patients.^{3,16} Treatment efficacy, defined as mean increase in Hb (g/dL) from baseline observed in the clinical trials, was used as an effectiveness measure in the model.

Model framework

The model follows an ND-CKD patient who receives one of four outpatient IDA treatments over a 5-week time horizon. During treatment, a patient gains clinical benefits in the form of Hb increase and incurs therapy acquisition and administration costs, AEs, and medical management specific to the treatment. A patient receives only one treatment and may not switch during the time horizon. The model accounts for the cost due to partial vial wasting (the number of vials needed per administration is rounded up to the nearest integer). Partial vial wasting was relevant to the weight-based dosing of the ESAs. A patient may discontinue treatment at the end of each week up to week 4 (according to treatment-specific discontinuation observed in trials in intent-to-treat [ITT] population) with therapy costs accrued during a week reduced proportionally to the discontinuation rate in that week.

Model inputs include patient characteristics, therapy efficacy, and the cost of therapy acquisition and administration, medical management, and management of therapy-associated AEs. Model outputs include the average cost per g/dL increase in Hb for each treatment (to standardize for differences in effectiveness), incremental cost compared to FER monotherapy, and incremental cost per incremental change in Hb level.

The model also considers selected patient subgroups that reflect quartiles of baseline Hb levels observed in the

trials (<9.55 g/dL, 9.55–10.05 g/dL, 10.05–10.45 g/dL, and ≥10.45 g/dL). In each subgroup, efficacy of each treatment is assumed equal to the efficacy observed in clinical trials.

Model inputs and data sources

Clinical inputs

Clinical inputs, including patient weight and baseline Hb, treatment efficacy, vial size/pill strength, ESA utilization distribution, and clinical safety data inclusive of AE types and rates, were obtained from data pooled from two Phase III clinical trials – NCT00255424 (N = 304) and NCT00255437 (N = 303).^{3,16} Trial summaries are presented in Table 1 and key clinical input values in Table 2.

Patient weight and baseline Hb level were determined as the mean baseline weight and Hb level of all patients pooled from both trials regardless of treatment. Treatment efficacy is not dependent on pill strength/vial size used and is determined as the mean increase in Hb from baseline through day 35 (week 5) among ITT patients who received that treatment.

Utilization rates of ESAs considered in the model were based on clinical trial data (42% of patients had darbepoetin alfa and 58% had epoetin alfa). For a patient receiving a treatment that includes an ESA, outcomes are determined for the treatment with darbepoetin alfa and epoetin alfa separately and then weighted based on their utilization rates.

All AEs observed in the clinical trials, regardless of assessment of causality, were included in this analysis and

were categorized as serious or nonserious. Serious AEs (SAEs) include any patient outcome that is life-threatening, resulted in death, patient disability, inpatient admission or prolonged hospitalization, congenital anomaly, birth defect, or permanent damage. Non-SAEs include any AEs observed that were otherwise not classified as an SAE in the clinical trials. Due to similar occurrence rates and a large difference between costs of SAE management and of non-SAE management, the effect of non-SAEs on the cost of AE management was assumed negligible compared with that of SAEs. Additional analysis of AEs confirmed that the effects of AEs on the model were minimal for various levels of individual AE costs. The SAE rate is calculated as the number of events over total number of patients on a specific treatment among all patients pooled from the two trials (Table 3).

Dose and administration frequency of each treatment were extracted from prescribing information for FER and both ESAs, while clinical trial data were used for oral iron.^{14,15,17} Oral iron (ferrous fumarate) was prescribed at a dose of 100 mg of elemental iron twice daily for the first 21 days of the time horizon. The model assumes a starting dose for adult ND-CKD patients as recommended by the prescribing information of each ESA: 50 units/kg three times weekly subcutaneously for epoetin alfa and 0.45 µg/kg subcutaneously at 4-week intervals for darbepoetin alfa.^{14,15} FER administration follows the recommended schedule of 510 mg on day 1 and a second 510 mg dose 3–8 days later. Therapy

Table 1 Summary of clinical data sources

Clinical data	NCT00255424	NCT00255437
Study design	5-week Phase III, RCT	5-week Phase III, RCT
Study size, n ^a	304	303
FER, n (%)	228 (75)	226 (75)
Oral iron, n (%)	76 (25)	77 (25)
N (%) with ESA use at baseline in ITT population	116 (38)	129 (43)
FER	83 (36)	95 (42)
Oral iron	33 (43)	34 (44)
Administration schedule		
FER	510 mg via IV on day 0 and 5 (±3) days after first dose	510 mg via IV on day 0 and 5 (±3) days after first dose
Oral iron	200 mg orally daily from day 0 through day 21	200 mg orally daily from day 0 through day 21
Day 21 efficacy, ^b mean, g/dL		
FER	0.48	0.65
FER + ESA	0.98	1.24
Oral iron	0.09	0.28
Oral iron + ESA	0.34	0.50
Day 35 efficacy, ^b mean, g/dL		
FER	0.62	0.91
FER + ESA	1.16	1.64
Oral iron	0.13	0.25
Oral iron + ESA	0.19	0.86

Notes: ^aTreatment randomization of FER vs. oral iron was 3:1. ^bEfficacy is defined as the change in Hb from baseline.

Abbreviations: ESA, erythropoietin-stimulating agent; FER, ferumoxytol; Hb, hemoglobin; ITT, intent-to-treat; IV, intravenous; RCT, randomized controlled trial.

Table 2 Key clinical input values

Clinical inputs	Value (in USD)				Reference
Weight, mean (SD), kg	88.46 (23.63)				NCT00255424, NCT00255437 ^{3,16}
Baseline Hb, mean (SD), g/dL	9.90 (0.73)				NCT00255424, NCT00255437 ^{3,16}
ESA utilization distribution, %	DPA	EPO			NCT00255424, NCT00255437 ^{3,16}
	42	58			
Vial size/pill strength	Value				Feraheme PI ¹⁷ Assumption Assumption Assumption
FER, mg/17 mL	510				
Oral iron, mg	50				
Darbepoetin alfa, µg/mL	100				
EPA, units/mL	2,000				
	FER	FER + ESA	Oral iron	Oral iron + ESA	
Treatment efficacy, ^a mean (SD), g/dL	0.76 (1.03)	1.42 (1.44)	0.19 (0.75)	0.53 (1.20)	NCT00255424, NCT00255437 ^{3,16}
No. of medical management events					
CBC	2	2	2	2	KDOQI Anemia Guidelines, Aranesp PI, Procrit PI ^{14,15,18}
Absolute reticulocyte count	1	1	1	1	KDOQI Anemia Guidelines, Aranesp PI, Procrit PI ^{14,15,18}
TSAT	2	2	2	2	KDOQI Anemia Guidelines, Aranesp PI, Procrit PI ^{14,15,18}
Serum ferritin	2	2	2	2	KDOQI Anemia Guidelines, Aranesp PI, Procrit PI ^{14,15,18}
Hb	0	4	0	4	Aranesp PI, Procrit PI ^{14,15}
Blood draw	2	6	2	6	Assumption
Nurse consultation	0	4	0	4	Assumption based on KDOQI Anemia Guidelines ¹⁸
Physician visit	2	2	2	2	Assumption based on KDOQI Anemia Guidelines ¹⁸

Note: ^aEfficacy is defined as the change in Hb from baseline.

Abbreviations: CBC, complete blood count; DPA, darbepoetin alfa; EPA, epoetin alfa; ESA, erythropoietin-stimulating agent; FER, ferumoxytol; Hb, hemoglobin; KDOQI, Kidney Disease Outcomes Quality Initiative; PI, prescribing information; TSAT, transferrin saturation.

vial size or pill strength determines the number of vials or pills required in each administration. FER vial size and oral iron pill strengths, 510 mg/17 mL and 50 mg, respectively, are equivalent to those used in the trials. Vial sizes of 100 µg/mL and 2,000 units/mL/vial are assumed for darbepoetin alfa and epoetin alfa, respectively.

Medical management events consider routine medical procedures associated with IDA treatment and include relevant laboratory tests, blood draw (i.e., venipuncture), nurse consultation, and physician visit. Relevant laboratory tests include complete blood count (CBC), absolute reticulocyte count, Hb, transferrin saturation (TSAT), and serum ferritin. All tests occurring in the same week are assumed to be measured in a single blood draw. The frequency of medical management events, expressed as the number of events occurring over 5 weeks, was determined from the US National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Anemia Guidelines and prescribing information for both ESAs and is specific to each treatment.^{14,15,18}

Cost inputs

Cost inputs include drug acquisition and administration costs, cost of treating SAEs, and medical management cost. Key cost inputs used in the model are presented in Table 4. Drug acquisition cost inputs are considered on a per vial or per pill basis and are represented as wholesale acquisition cost (WAC) retrieved from RED BOOKTM 2016.¹⁹ Administration cost inputs are considered for each administration, vary by the administration route, and are derived from 2015B Physician Fee Schedule for corresponding current procedural terminology (CPT) codes.²⁰ IV administration considered the cost of up to 1 hour of infusion time as well as additional post-dose monitoring. FER and ESAs are administered intravenously and subcutaneously, respectively. No administration cost is assumed for oral iron. Costs associated with SAE management (Table 3) are based on Medicare Severity-Diagnosis-Related Group (MS-DRG) classifications, DRG relative weights, and the base payment rate from Centers for Medicare and Medicaid Services (CMS) data.²¹

Medical management costs are determined by multiplying the cost of each medical event by the total number

Table 3 SAE rate input values, costs referenced from IPPS FY 2016 Correction Notice,²¹ rates from NCT00255424 and NCT00255437^{3,16}

SAEs	Cost per event (USD)	FER, n (%)	FER + ESA, n (%)	Oral iron, n (%)	Oral iron + ESA, n (%)
Acute coronary syndrome	\$3,795.88	0 (0)	1 (0.59)	0 (0)	0 (0)
Acute tubular necrosis	\$5,555.32	0 (0)	0 (0)	0 (0)	1 (1.56)
Adrenal insufficiency	\$5,978.79	1 (0.37)	0 (0)	0 (0)	0 (0)
Alteration in mental status	\$4,344.56	0 (0)	1 (0.59)	0 (0)	0 (0)
Anemia	\$5,062.74	0 (0)	0 (0)	1 (1.18)	3 (4.69)
Angina pectoris	\$3,597.43	0 (0)	0 (0)	1 (1.18)	0 (0)
Azotemia	\$4,095.32	0 (0)	0 (0)	1 (1.18)	0 (0)
Bradycardia	\$4,636.91	0 (0)	0 (0)	0 (0)	2 (3.13)
Cardiac arrest	\$3,831.90	1 (0.37)	1 (0.59)	0 (0)	0 (0)
Cardiac failure chronic	\$5,733.09	0 (0)	1 (0.59)	0 (0)	0 (0)
Cardiac failure congestive	\$5,733.09	3 (1.12)	1 (0.59)	1 (1.18)	0 (0)
Cardio-pulmonary arrest	\$3,831.90	0 (0)	1 (0.59)	0 (0)	0 (0)
Chest pain	\$3,910.46	2 (0.75)	0 (0)	0 (0)	0 (0)
Cholelithiasis	\$6,232.75	1 (0.37)	0 (0)	0 (0)	0 (0)
Chronic obstructive airways disease	\$5,505.11	0 (0)	1 (0.59)	0 (0)	0 (0)
Coronary artery disease	\$3,795.88	1 (0.37)	0 (0)	0 (0)	0 (0)
Diverticulitis	\$4,370.54	1 (0.37)	0 (0)	0 (0)	0 (0)
Dyspnea	\$4,306.17	0 (0)	0 (0)	0 (0)	1 (1.56)
Gangrene	\$5,902.60	0 (0)	1 (0.59)	0 (0)	1 (1.56)
Gastritis	\$4,370.54	0 (0)	0 (0)	1 (1.18)	0 (0)
Gastroenteritis	\$4,370.54	0 (0)	0 (0)	1 (1.18)	0 (0)
Gastroparesis	\$4,370.54	1 (0.37)	0 (0)	0 (0)	0 (0)
Grand mal seizure	\$4,690.66	1 (0.37)	0 (0)	0 (0)	0 (0)
Hypercalcemia	\$4,264.82	1 (0.37)	0 (0)	0 (0)	0 (0)
Hyperkalemia	\$4,264.82	1 (0.37)	0 (0)	0 (0)	0 (0)
Hypertensive crisis	\$3,913.41	1 (0.37)	0 (0)	0 (0)	0 (0)
Hypervolemia	\$4,264.82	0 (0)	0 (0)	1 (1.18)	0 (0)
Hypoglycemia	\$4,998.37	1 (0.37)	0 (0)	0 (0)	1 (1.56)
Hypoglycemic shock	\$4,998.37	1 (0.37)	0 (0)	0 (0)	0 (0)
Hypotension	\$4,506.38	1 (0.37)	0 (0)	0 (0)	1 (1.56)
Hypothermia	\$4,344.56	0 (0)	0 (0)	0 (0)	1 (1.56)
Hypovolemia	\$4,264.82	0 (0)	1 (0.59)	0 (0)	0 (0)
Hypoxia	\$4,821.77	1 (0.37)	0 (0)	0 (0)	0 (0)
Hypoxic encephalopathy	\$5,952.80	0 (0)	1 (0.59)	0 (0)	0 (0)
Ischemic cardiomyopathy	\$3,795.88	1 (0.37)	0 (0)	0 (0)	0 (0)
Loss of consciousness	\$4,506.38	0 (0)	0 (0)	0 (0)	1 (1.56)
Lower back pain	\$5,107.63	0 (0)	1 (0.59)	0 (0)	0 (0)
Nausea	\$4,370.54	0 (0)	0 (0)	1 (1.18)	0 (0)
Pancreatitis	\$5,210.99	0 (0)	0 (0)	1 (1.18)	0 (0)
Peripheral vascular disease	\$5,902.60	0 (0)	1 (0.59)	0 (0)	0 (0)
Pneumonia	\$5,726.00	1 (0.37)	1 (0.59)	1 (1.18)	2 (3.13)
Pulmonary edema	\$7,243.88	1 (0.37)	0 (0)	2 (2.35)	0 (0)
Renal failure	\$5,555.32	1 (0.37)	1 (0.59)	1 (1.18)	1 (1.56)
Scrotal swelling	\$4,629.23	0 (0)	1 (0.59)	0 (0)	0 (0)
Supraventricular tachycardia	\$4,636.91	0 (0)	1 (0.59)	0 (0)	0 (0)
Syncope	\$4,506.38	0 (0)	2 (1.18)	0 (0)	0 (0)
Transient ischemic attack	\$4,268.37	0 (0)	1 (0.59)	0 (0)	0 (0)
Ulcerative esophagitis	\$4,370.54	1 (0.37)	0 (0)	0 (0)	0 (0)
Ventricular fibrillation	\$4,636.91	1 (0.37)	0 (0)	0 (0)	0 (0)
Vomiting	\$4,370.54	0 (0)	0 (0)	1 (1.18)	0 (0)

Abbreviations: ESA, erythropoietin-stimulating agent; FER, ferumoxytol; FY, financial year; IPPS, inpatient prospective payment system; SAEs, serious adverse events.

of occurrences of that event within the 5-week treatment period. Individual medical management event costs were derived from the Clinical Diagnostic Laboratory Fee

Schedule and Physician Fee Schedule published by the CMS and Medical Expenditure Panel Survey (MEPS) Statistical Briefs.^{22,23}

Table 4 Key cost input values

Cost inputs	Value (in USD)	Reference
Therapy acquisition cost, WAC per vial/pill		
FER, mean (SD)	\$645.36 (\$64.54)	RED BOOK™ 2016 ¹⁹
Oral iron, mean (SD)	\$0.18 (\$0.02)	RED BOOK™ 2016 ¹⁹
Darbepoetin alfa, mean (SD)	\$744.80 (\$74.48)	RED BOOK™ 2016 ¹⁹
Epoetin alfa, mean (SD)	\$44.62 (\$4.46)	RED BOOK™ 2016 ¹⁹
Therapy administration cost, per administration		
FER, mean (SD)	\$152.44 (\$15.24)	Physician Fee Schedule 2015B, CMS ²⁰
Oral iron, mean (SD)	\$0.00 (\$0.00)	Assumption
Darbepoetin alfa, mean (SD)	\$53.54 (\$5.35)	Physician Fee Schedule 2015B, CMS ²⁰
Epoetin alfa, mean (SD)	\$53.54 (\$5.35)	Physician Fee Schedule 2015B, CMS ²⁰
Cost per medical management event		
CBC	\$10.59	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
Absolute reticulocyte count	\$5.45	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
TSAT	\$17.39	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
Serum ferritin	\$18.57	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
Hb	\$3.23	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
Blood draw	\$3.00	Clinical Diagnostic Laboratory Fee Schedule 2016, CMS ²³
Nurse consultation	\$74.45	Physician Fee Schedule 2015B, CMS ²⁰
Physician visit	\$169.48	MEPS Statistical Brief #484: Expenses for Office-Based Physician Visits by Specialty, 2013 ²²

Abbreviations: CBC, complete blood count; CMS, Centers for Medicare and Medicaid Services; FER, ferumoxytol; Hb, hemoglobin; MEPS, Medical Expenditure Panel Survey; TSAT, transferrin saturation; WAC, wholesale acquisition cost.

Analyses

The primary outcomes analyzed were overall cost and cost-effectiveness (expressed as average cost per g/dL increase in Hb) for each treatment, and the incremental cost and incremental cost-effectiveness of each treatment compared to FER monotherapy.

Overall cost is calculated as the sum of total therapy cost, average AE cost per patient, and total medical management cost. Treatment cost-effectiveness is determined as the ratio of the overall treatment costs and its efficacy. Incremental cost is the cost difference, while incremental efficacy is the difference in Hb increase (from baseline) between a treatment of interest and FER monotherapy. Incremental cost-effectiveness is the ratio of the incremental cost and incremental efficacy. These outcomes are stratified by cost components, including therapy costs, SAE costs and medical management costs for each treatment.

One-way sensitivity analyses were performed to identify cost drivers and multivariate probabilistic sensitivity analysis (PSA) to assess the stability of the results. One-way sensitivity was analyzed as a series of univariate variations in key parameters (weight, baseline Hb level, efficacy, cost per vial or per pill, administration costs, costs due to SAE management, and medical management costs). Each key parameter is varied (increased/decreased) by 20% of its default value, while all other parameters are kept constant at their default values. The multivariate sensitivity analysis utilized 1,000

iterative Monte Carlo simulations for each treatment pathway to examine the effects of simultaneous variation in multiple input parameters based on random sampling from the following distributions: normal (patient weight, baseline Hb level, efficacy), gamma (therapy acquisition, administration costs), and uniform (AEs).

Results

Base case

The total direct cost for FER monotherapy was \$2,489 as compared with \$1,298 for oral iron monotherapy. The majority of the overall cost of the FER monotherapy treatment was attributed to drug acquisition cost (51.9%), while the total cost of oral iron monotherapy was mostly composed of AE costs (64.7%). The concurrent use of ESA resulted in an incremental cost of \$2,727 for FER and \$2,965 for oral iron, with the majority of the cost increase in product acquisition cost. Comparison of the results for the analyzed treatments is presented in Table 5.

FER is the most cost-effective treatment compared to oral iron with or without ESA use. FER monotherapy is approximately two times more cost-effective than oral iron monotherapy (\$3,275 vs. \$6,833 per 1 g/dL increase in Hb, respectively). In combination with ESA, FER remains more cost-effective than oral iron (\$3,673 vs. \$8,044 per 1 g/dL increase in Hb, respectively).

At base case, the model reflects general clinical practice where vials with remaining drug volume are discarded. Vial

Table 5 Overall cost and cost-effectiveness results for each treatment strategy, in the overall patient population and in different baseline Hb patient subgroups

Results	FER	FER + ESA	Oral iron	Oral iron + ESA
Overall patient population				
Total therapy costs	\$1,595.60	\$3,896.59	\$15.12	\$2,316.11
Therapy acquisition cost	\$1,290.72	\$3,080.93	\$15.12	\$1,805.33
Therapy administration cost	\$304.88	\$815.65	\$0.00	\$510.77
AE costs	\$450.10	\$553.03	\$839.62	\$1,180.73
Medical management costs	\$443.51	\$766.23	\$443.51	\$766.23
Physician and nurse costs	\$338.96	\$636.76	\$338.96	\$636.76
Laboratory test costs	\$104.55	\$129.47	\$104.55	\$129.47
Total costs	\$2,489.21	\$5,215.85	\$1,298.25	\$4,263.07
Efficacy, ^a g/dL Hb increase	0.76	1.42	0.19	0.53
Cost per 1 g/dL Hb increase	\$3,275.27	\$3,673.13	\$6,832.89	\$8,043.53
Baseline Hb patient subgroups				
<9.55 g/dL baseline Hb				
Overall costs	\$2,037.95	\$3,966.60	\$1,298.25	\$3,465.08
Efficacy, ^a g/dL Hb increase	1.09	1.53	0.48	0.99
Cost per 1 g/dL Hb increase	\$1,874.84	\$2,587.48	\$2,676.80	\$3,486.00
9.55–10.05 g/dL baseline Hb				
Overall costs	\$2,037.95	\$3,966.60	\$1,298.25	\$3,465.08
Efficacy, ^a g/dL Hb increase	0.77	1.80	0.12	0.36
Cost per 1 g/dL Hb increase	\$2,657.04	\$2,206.12	\$11,096.15	\$9,679.00
10.05–10.45 g/dL baseline Hb				
Overall costs	\$2,037.95	\$3,966.60	\$1,298.25	\$3,465.08
Efficacy, ^a g/dL Hb increase	0.57	0.99	0.22	0.82
Cost per 1 g/dL Hb increase	\$3,575.35	\$4,002.63	\$5,982.72	\$4,230.87
≥10.45 g/dL baseline Hb				
Overall costs	\$2,037.95	\$3,966.60	\$1,298.25	\$3,465.08
Efficacy, ^a g/dL Hb increase	0.63	1.12	0.00	–0.03
Cost per 1 g/dL Hb increase	\$3,255.51	\$3,529.00	–	N/A ^b

Notes: ^aEfficacy values were determined as the mean of pooled g/dL increase (rounded to two decimals) in Hb values observed in individual patient data of two Phase III RCTs of FER vs. oral iron in ND-CKD patients (NCT00255424 and NCT00255437).^{3,16} ^bDue to the demonstrated negative efficacy, cost per 1 g/dL increase is not applicable.

Abbreviations: AE, adverse event; CKD, chronic kidney disease; ESA, erythropoietin-stimulating agent; FER, ferumoxytol; Hb, hemoglobin; N/A, not applicable; ND-CKD, non-dialysis-dependent CKD; RCTs, randomized controlled trials.

wasting increases the cost of therapy acquisition in strategies with ESA. When vial wasting is not considered, FER remains more cost-effective than oral iron with or without ESA use (without ESA: \$3,275 vs. \$6,833; with ESA: \$3,192 vs. \$6,755).

Analysis of the treatment discontinuation showed minimal impact due to low discontinuation rates observed in the trials underlying the model, with FER remaining cost-effective compared with oral iron with or without concurrent ESA use (without ESA: \$3,266 vs. \$6,831; with ESA: \$3,641 vs. \$7,810).

FER, with or without ESA, was more cost-effective than oral iron irrespective of baseline Hb levels (Table 5). The cost-effectiveness of FER-based treatment does not greatly differ across the baseline Hb subgroups, while the difference in cost-effectiveness of oral iron treatment across subgroups is more pronounced. The difference in cost-effectiveness of oral iron-based treatment across the subgroups was primarily due to difference in recorded treatment efficacies – with the g/dL increase in Hb in the ≥10.45 g/dL baseline Hb subgroup

reaching negative values, indicating a decrease in Hb. The outcomes for each subgroup are presented in Table 5.

Sensitivity analyses

The results of one-way sensitivity analyses are illustrated in the tornado graphs in Figure 1. Among the varied parameters, the primary driver of cost per g/dL increase in Hb for all treatments was week 5 efficacy. With the exception of oral iron monotherapy, the acquisition cost per vial/pill was the second strongest driver of cost per g/dL increase in Hb. For treatments with ESA use, patient weight was an important cost driver. A 20% decrease in patient weight resulted in improved cost-effectiveness, but changes were nonexistent when weight was increased. This one-sided weight change effect on the treatment cost is due to inclusion of vial wasting. For oral iron monotherapy, cost is significantly influenced by AE costs and medical management costs.

The mean values of all simulated 1,000 iteration outcomes from the PSA for incremental cost and efficacy of

Figure 1 Tornado graphs depicting one-way sensitivity analysis outcomes for FER, FER with ESA, oral iron, and oral iron with ESA.

Notes: The high bar (dark gray) represents the effect of a 20% increase from the base case value of the indicated variable on the cost per g/dL increase in Hb (in USD). The low bar (light gray) represents the effect of a 20% decrease from the base case value of the indicated variable on the cost per g/dL increase in Hb (in USD).

Abbreviations: ESA, erythropoietin-stimulating agent; FER, ferumoxytol; Hb, hemoglobin; SAE, serious adverse event.

other treatments with respect to FER demonstrated that FER is more cost-effective than oral iron. Similar patterns were observed across all patient subgroups, therefore validating the cost-effectiveness of FER.

Discussion

This analysis, which was primarily based on patient-level clinical trial data, strongly suggests that FER is associated with superior clinical and economic benefits in the

treatment of IDA in adult ND-CKD patients compared to oral iron.

With or without ESA, FER is cost-effective compared with oral iron in treating IDA due to higher treatment efficacy and lower AE rates. ESA use in ND-CKD patients has recently decreased in response to new anemia guidelines.²⁴ FER as a monotherapy is more cost-effective than in combination with ESA, likely reducing the need for ESA in ND-CKD patients when ESA use is optional. The impact of discontinuation on cost is negligible due to low discontinuation rates observed in the clinical trials. Vial wasting has no pronounced effect on the total treatment cost and only influences treatments that utilize ESAs. An analysis of vial size variation showed the same trends in cost-effectiveness.

The cost of oral iron-based treatments is predominantly driven by AE costs; AE management costs in FER-based treatments are approximately half of those in oral iron-based treatments. Different AE rates reported in the trials directly contribute to this AE management cost difference between oral iron- and FER-based treatments.

Both FER treatments are consistently more cost-effective than oral iron across all baseline Hb level subgroups. The superior cost-effectiveness of FER, with or without concurrent ESA, compared with oral iron treatments is more pronounced among patient subgroups with higher baseline Hb. FER is the most cost-effective in the subgroup with the lowest baseline Hb (<9.55 g/dL) due to the high efficacy observed.

Results were robust to the variation in costs and patient and therapy characteristics. Treatment efficacy, followed by therapy acquisition cost, is the main factor in determining the cost-effectiveness.

This analysis may be subject to limitations. The model is based on data from 5-week clinical trials; however, the 5-week treatment period was long enough for effects to be observed and achieve statistical significance, reflecting FER's advantage in providing more rapid IDA correction. After 5 weeks of treatment, the difference in the observed efficacy of FER and oral iron was larger than the difference in cost, further reinforcing FER's superior cost-effectiveness. While treatment with oral iron extending beyond 5 weeks may lead to better effectiveness, the extended treatment period may also be associated with additional medical management and AE costs that counteract the potential cost-effectiveness improvements. It is generally accepted that an increase in Hb of 1 g/dL after 1 month of treatment indicates an adequate response to treatment and that, while IV therapy can restore iron stores in a single course of treatment, oral iron therapy should be continued for 3 months after the anemia is cor-

rected to allow iron stores to become replenished.^{12,14,15,25} In a 6-month extension study, patients with IDA and a history of unsatisfactory oral iron therapy or in whom oral iron could not be used who had completed a randomized, double-blind, placebo-controlled trial were evaluated for IDA monthly. Those with persistent or recurrent IDA at any monthly evaluation received a further course of treatment. Overall, 61% of the patients did not require a second course of FER over the 6-month period.²⁶ The two RCTs in this study did not measure the quality of life. However, the effect of IDA and its treatment on patient reported outcomes, especially fatigue, has been studied. In a double-blind, placebo-controlled trial, patients with a history of unsatisfactory oral iron therapy, or in whom oral iron could not be used, had very poor baseline health-related quality of life (HRQoL) scores (Functional Assessment of Chronic Illness Therapy- Fatigue [FACIT-Fatigue], the Medical Outcomes Survey Short Form-36 [SF-36], and the Linear Analogue Scale Assessment [LASA], LASA-QOL), showing the levels of fatigue similar to those previously reported in anemic cancer patients. FER treatment resulted in clinically meaningful improvements in HRQoL, significantly greater than placebo, across all domains. The correlation of FACIT-Fatigue scores with Hb level (grouped in 0.5 g/dL categories) across the treatment period was high ($r = 0.97$, $P = 0.002$).^{27,28} These results were also observed among the subgroup of patients in this study with kidney disease.²⁹ The two RCTs used in the cost-effectiveness model reported in this study recruited just over 600 patients; however, the sample size met the power calculation and the sample size of these studies is consistent with the majority of studies investigating treatments for IDA. The analysis specifically studied the cost-effectiveness of FER and oral iron and may not be generalizable to other IV iron preparations, which may require more infusions and venipunctures to administer 1 g elemental iron. Finally, the model utilizes a snapshot of 2016 US cost data and does not take into consideration price fluctuations or regional variations; however, one-way sensitivity analysis evaluated 20% changes in each of the cost parameters assessing for possible price increases or decreases.

The model reflects practices observed in clinical trials. The results were determined from patient and treatment characteristics, including efficacies and AE occurrences, directly sourced from the trials. The analysis is based on patient data from the trials that have compared oral iron and FER treatments in a controlled environment with identical criteria for both treatment populations, which adds to the validity of the input values used while reducing potential biases and the number of assumptions.

Conclusion

This study strongly suggests that FER is a more cost-effective treatment for IDA in adult ND-CKD patients over a 5-week treatment period as compared with oral iron with or without ESA. FER as monotherapy is a more cost-effective option than in combination with ESA.

Acknowledgment

AMAG Pharmaceuticals funded this study and participated in the analysis and interpretation of the data, and in the preparation, review and approval of the manuscript for publication. In addition, all the authors were involved in the decision to submit the manuscript for publication and had the right to accept or reject comments or suggestions.

Disclosure

Naomi V Dahl, William E Strauss, and Robert F Kaper are employees of AMAG Pharmaceuticals. William E Strauss and Naomi V Dahl own stock in AMAG Pharmaceuticals. Frank Corvino and Marko Zivkovic have current consulting agreements with AMAG Pharmaceuticals. The authors report no other conflicts of interest in this work.

References

1. National Center for Chronic Disease Prevention and Health Promotion. *Chronic Kidney Disease Initiative-Protecting Kidney Health*. 2015. Available from: http://www.cdc.gov/diabetes/projects/pdfs/ckd_summary.pdf. Accessed July 24, 2017.
2. National Center for Chronic Disease Prevention and Health Promotion. *National Chronic Kidney Disease Fact Sheet 2014*. 2014. Available from: https://www.cdc.gov/diabetes/pubs/pdf/kidney_factsheet.pdf. Accessed July 24, 2017.
3. Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. *J Am Soc Nephrol*. 2008;19(8):1599–1605.
4. Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. *Patient Prefer Adherence*. 2008;2:195–200.
5. World Health Organization [webpage on the Internet]. *Iron Deficiency Anaemia: Assessment, Prevention and Control*. World Health Organization; 2001. Available from: http://www.who.int/iris/bitstream/10665/66914/http://apps.who.int/iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf?ua=1. Accessed July 24, 2017.
6. Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. *Am Fam Physician*. 2007;75(5):671–678.
7. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet*. 2013;382(9888):260–272.
8. Umbreit J. Iron deficiency: a concise review. *Am J Hematol*. 2005;78(3):225–231.
9. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. *PLoS One*. 2014;9(1):e84943.
10. Stoltzfus RJ, Dreyfuss ML. Guidelines for the Use of Iron Supplements to Prevent and Treat Iron Deficiency Anemia. Washington, DC: ILSI Press; 1998.
11. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. *Am J Med*. 2008;121(11):943–948.
12. Shepshelovich D, Rozen-Zvi B, Avni T, Gafer U, Gafer-Gvili A. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. *Am J Kidney Dis*. 2016;68(5):677–690.
13. National Institute of Diabetes and Digestive and Kidney Diseases [webpage on the Internet]. *Anemia in Chronic Kidney Disease*. 2014. Available from: <https://www.niddk.nih.gov/health-information/health-topics/kidney-disease/anemia-in-kidney-disease-and-dialysis/Pages/facts.aspx>. Accessed July 24, 2017.
14. Aranesp [package insert]. Thousand Oaks, CA: Amgen Inc; 2017. Available from: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=0fd36cb9-c4f6-4167-93c9-8530865db3f9&type=pdf&name=0fd36cb9-c4f6-4167-93c9-8530865db3f9>.
15. Procrit [package insert]. Horsham, PA: Janssen Products, LP; 2017. Available from: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=0c721ba4-ae19-417f-aae1-221ed1a0866a&type=pdf&name=0c721ba4-ae19-417f-aae1-221ed1a0866a>. Accessed July 24, 2017.
16. Fishbane S, Bolton WK, Winkelmayer WC, Strauss W, Li Z, Pereira BJG. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. *Clin Nephrol*. 2012;78(3):181–188.
17. Feraheme [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc.; 2015. Available from: <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=32b0e320-a739-11dc-a704-0002a5d5c51b&type=pdf&name=32b0e320-a739-11dc-a704-0002a5d5c51b>. Accessed July 24, 2017.
18. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. New York City, NY: National Kidney Foundation; 2006.
19. Micromedex Solutions [webpage on the Internet]. *RED BOOK Online™*. Greenwood, CO: 2016. Available from: <http://www.micromedexsolutions.com/micromedex2/librarian>. Accessed July 24, 2017.
20. Centers for Medicare & Medicaid Services [webpage on the Internet]. *National Physician Fee Schedule Relative Value File Calendar Year 2015B*. 2015. Available from: <https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx>. Accessed July 24, 2017.
21. Centers for Medicare & Medicaid Services [webpage on the Internet]. *FY 2016 IPPS Final Rule, Correction Notice and Consolidated Appropriations Act of 2016 Tables*. 2016. Available from: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2016-IPPS-Final-Rule-Home-Page-Items/FY2016-IPPS-Final-Rule-Tables.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending>. Accessed July 24, 2017.
22. Machlin SR, Adams SA. *MEPS Statistical Brief #484 : Expenses for Office-Based Physician Visits by Specialty, 2013*. 2013. Available from: https://meps.ahrq.gov/data_files/publications/st484/stat484.pdf. Accessed July 24, 2017.
23. Centers for Medicare & Medicaid Services [webpage on the Internet]. *Clinical Laboratory Fee Schedule 2016*. 2016. Available from: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Clinical-LabFeeSched/Clinical-Laboratory-Fee-Schedule-Files-Items/16CLAB.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending>. Accessed July 24, 2017.
24. St Peter W, Guo H, Kabadi S, et al. Anemia treatment pattern changes in non-dialysis-dependent chronic kidney disease patients before and after revised food and drug administration label and new anemia guidelines for erythropoiesis-stimulating agents. Chicago, USA. Presented at: *The American Society of Nephrology*; 2016: FR-PO767.
25. Short M, Domagalski J. Iron deficiency anemia: evaluation and management. *Am Fam Physician*. 2013;87(2):98–104.
26. Vadhan-Raj S, Ford DC, Dahl NV, et al. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: results of a phase III, open-label, 6-month extension study. *Am J Hematol*. 2016;91(2):E3–E5.
27. Vadhan-Raj S, Strauss W, Ford D, et al. Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. *Am J Hematol*. 2014;89(1):7–12.
28. Strauss WE, Dahl NV, Vadhan-Raj S, et al. Effects of IV iron treatment with ferumoxytol on health-related quality of life of patients with iron deficiency anemia. *J Community Support Oncol*. 2016;14(8):342–350.
29. Dahl N, Strauss W, Bernard K. Effect of ferumoxytol on fatigue in patients with iron deficiency anemia (IDA) and kidney disease. *American Society of Nephrology (ASN) Annual Meeting*. Philadelphia, PA: 2014. *J Am Soc Nephrol*. 2014;25:259A.

ClinicoEconomics and Outcomes Research

Dovepress

Publish your work in this journal

ClinicoEconomics and Outcomes Research is an international, peer-reviewed open-access journal focusing on health technology assessment, pharmacoeconomics and outcomes research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems

organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal>